TOM FORD Announces Appointment of Haider Ackermann as Creative Director
4.9.2024 15:30:00 CEST | Business Wire | Press release
TOM FORD announces the appointment of Haider Ackermann as Creative Director, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904332237/en/
Haider Ackermann appointed Creative Director, TOM FORD. (Photo Credit: Ethan James Green)
In his new role, Ackermann will assume the creative leadership across all TOM FORD fashion categories, including menswear, womenswear, accessories, and eyewear, and guide the creative vision for the overall brand. TOM FORD is owned by The Estée Lauder Companies Inc. (NYSE:EL) with the fashion business licensed to the Ermenegildo Zegna Group (NYSE:ZGN) and the eyewear business licensed to Marcolin SpA.
Founder Tom Ford said, “I have long been a great fan of Haider’s work. I find both his womenswear and menswear equally compelling. He is an incredible colorist, his tailoring is sharp, and above all he is modern. We share many of the same historical references, and I could not be more excited to see what he does with the brand. I suspect that I will be the first on my feet to applaud after his show in March.”
A French national born in Bogotá, Colombia, Ackermann's upbringing spanned Ethiopia, Chad, Algeria, The Netherlands, and Belgium, where he studied fashion at the Royal Academy of Fine Arts in Antwerp. Known for blending luxurious fabrics with impeccable tailoring, Ackermann has garnered acclaim for his avant-garde, yet wearable designs favored by celebrities.
“It is with tremendous pride that I will seek to honor the legacy of Tom Ford, a man I have long admired and have the utmost respect for,” said Ackermann. “I am much looking forward to what lies ahead.”
Ackermann's first collection will debut at Paris Fashion Week in March 2025. He will be based in Paris, reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies, and to Lelio Gavazza, CEO, TOM FORD FASHION, Ermenegildo Zegna Group.
“Haider stands out as one of the world's most visionary and inspiring talents in fashion. He draws on his deep affinity for global culture and the arts to create arresting fashion and memorable emotional connections. He is the ideal steward to usher TOM FORD into the future," said Jesel.
“I am extremely pleased to welcome Haider as Creative Director of TOM FORD. His unparalleled creativity, which is aligned with the brand's DNA, as well as his renowned experience in luxury will be instrumental in driving the fashion business forward during its next important phase of expansion. Working alongside the talented team at TOM FORD FASHION, Haider’s modern vision, for both men’s and women’s wear, will be essential as we advance and execute the many projects we have in development,” said Gavazza.
About TOM FORD
TOM FORD is a global design house offering exceptional luxury products across women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand has a presence in more than 100 markets globally and is widely recognized as the architect of luxury glamour. In 2023, The Estée Lauder Companies became the sole owner of the TOM FORD brand and all its intellectual property. In connection with the acquisition, The Estée Lauder Companies established long term licenses with Ermenegildo Zegna Group for TOM FORD FASHION and Marcolin for TOM FORD EYEWEAR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904332237/en/
Contacts
Press Contact:
Press Contact:
Giuseppe Torrisi
TOM FORD, Global Communications Director
Giuseppe.Torrisi@tomfordfashion.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom